AOD-9604 in Prospect — Fat Loss Peptide Research Guide
AOD-9604 research guide for Prospect. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Research-Grade AOD-9604 for Prospect Investigators
Most researchers seeking out AOD-9604 in Prospect quickly find that local retail options are essentially nonexistent. This matters because AOD-9604 quality varies dramatically across the market — from analytically confirmed high-purity product to mislabeled or underdosed compounds — and the vendor controls every quality variable. Vendors worth sourcing from proactively publish batch-matched Certificates of Analysis showing HPLC chromatograms, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the exact batch you are purchasing. The sections below cover what Prospect researchers need to know about finding, evaluating, and storing AOD-9604 for scientific research use.
AOD-9604 Mechanisms Explained
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Prospect studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Sourcing Research-Grade AOD-9604
The first step for any Prospect researcher sourcing AOD-9604 is finding vendors with verified community track records — commercial rankings reflect SEO budgets rather than product quality. A COA for AOD-9604 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all batch-matched. Community reputation in research forums is a useful additional signal to COA verification — vendors with sustained positive community feedback have built their reputation on real product performance. Bacteriostatic water is the standard reconstitution medium for AOD-9604 — it contains 0.9% benzyl alcohol that prevents microbial contamination and extends reconstituted shelf life to 30 days refrigerated.
Order AOD-9604 — ships to Prospect
COA-verified · International tracking · Research grade
All use of AOD-9604 in Prospect or anywhere constitutes research use — this compound is not approved for human therapeutic use, and all handling should comply with standard research safety practices. Proper handling of AOD-9604 requires strict sterile technique during reconstitution — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and temperature control throughout the entire workflow. Endotoxin testing in the AOD-9604 COA is absolutely required — gram-negative bacterial endotoxins can trigger severe inflammatory responses at minute levels, and no discount compensates for this missing data. Protocol documentation — recording exactly what was used, when, and how — is a research best practice for AOD-9604 that ensures unusual findings can be explained.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
